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Pseudomonas aeruginosa exploits intrinsic and acquired resistance mechanisms to resist almost 27 
every antibiotic used in chemotherapy. Antimicrobial resistance in P. aeruginosa isolated from 28 
cystic fibrosis (CF) patients is further enhanced by the occurrence of hypermutator strains, a 29 
hallmark of chronic CF infections. However, the within-patient genetic diversity of P. aeruginosa 30 
populations related to antibiotic resistance remains unexplored. Here, we show the evolution of 31 
the mutational resistome profile of a P. aeruginosa hypermutator lineage by performing 32 
longitudinal and transversal analyses of isolates collected from a CF patient throughout 20 years 33 
of chronic infection. Our results show the accumulation of thousands of mutations with an overall 34 
evolutionary history characterized by purifying selection. However, mutations in antibiotic 35 
resistance genes appear to be positively selected, driven by antibiotic treatment. Antibiotic 36 
resistance increased as infection progressed towards the establishment of a population constituted 37 
by genotypically diversified coexisting sub-lineages, all of which converged to multi-drug 38 
resistance. These sub-lineages emerged by parallel evolution through distinct evolutionary 39 
pathways, which affected genes of the same functional categories. Interestingly, ampC and fstI, 40 
encoding the β-lactamase and penicillin-binding protein 3, respectively, were found among the 41 
most frequently mutated genes. In fact, both genes were targeted by multiple independent 42 
mutational events, which led to a wide diversity of coexisting alleles underlying β-lactam 43 
resistance. Our findings indicate that hypermutators, apart from boosting antibiotic resistance 44 
evolution by simultaneously targeting several genes, favor the emergence of adaptive innovative 45 
alleles by clustering beneficial/compensatory mutations in the same gene, hence expanding P. 46 
aeruginosa strategies for persistence. 47 
IMPORTANCE  48 
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By increasing mutation rates, hypermutators boost antibiotic resistance evolution by enabling 49 
bacterial pathogens to fully exploit their genetic potential and achieve resistance mechanisms for 50 
almost every known antimicrobial agent. Here, we show how co-existing clones from a P. 51 
aeruginosa hypermutator lineage that evolved during 20 years of chronic infection and antibiotic 52 
chemotherapy, converged to multidrug resistance by targeting genes from alternative genetic 53 
pathways that are part of the broad P. aeruginosa resistome. Within this complex assembly of 54 
combinatorial genetic changes, in some specific cases, multiple mutations are needed in the same 55 
gene to reach a fine tuned resistance phenotype. Hypermutability enables this genetic edition 56 
towards higher resistance profiles by recurrently targeting these genes, thus promoting new 57 
epistatic relationships and the emergence of innovative resistance-conferring alleles. Our findings 58 
help to understand this link between hypermutability and antibiotic resistance, a key challenge for 59 
the design of new therapeutic strategies. 60 




Antibiotic resistance has emerged as a global health concern with serious economic, social and 63 
political implications. Accordingly, it is becoming widely accepted that we are close to a post-64 
antibiotic era due to the increasing occurrence of multidrug-resistant pathogens and the failure to 65 
compensate this phenomenon with drug discovery (1).  66 
Among high-risk pathogens, Pseudomonas aeruginosa is one of the leading causes of nosocomial 67 
infections and the third most common bacterium isolated from infections acquired in intensive 68 
care units (2). Likewise, P. aeruginosa chronically infects the airways of cystic fibrosis (CF) 69 
patients and constitutes their main cause of morbidity and mortality (3).  70 
The effective intrinsic and acquired resistance mechanisms of P. aeruginosa to different types of 71 
antibiotics (4) and the emergence of multidrug-resistant (MDR) clones (5), severely compromise 72 
the treatment of these infections. Notably, several resistance genes, including different classes of 73 
carbapenemases, have spread among an increasing number of P. aeruginosa clones through 74 
horizontal gene transfer. In many cases, this makes colistin, and to some extent amikacin, the only 75 
available drugs to treat MDR P. aeruginosa infections (2).  76 
Intrinsic mechanisms of resistance involve mutations in chromosomal genes leading to the 77 
inactivation of the carbapenem porin OprD, the overexpression of AmpC and the upregulation of 78 
efflux pumps (4, 6, 7). Importantly, the concomitant accumulation of these mutations can lead to 79 
the emergence of MDR strains, which constitute a major concern in clinical setting (5).  80 
Frequently, the acquisition of these adaptive mutations is enhanced by increments in mutation 81 
rates like that observed in hypermutator strains of P. aeruginosa. Thus, it has been reported that 82 
36-54% of chronically infected CF patients are infected with hypermutator strains of P. 83 
aeruginosa, which are deficient in the DNA mismatch repair (MMR) system (8-13). The 84 
hypermutator phenotype has been correlated with increased development of antibiotic resistance 85 
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(8, 12, 14-16), acquisition of chronic infection adaptive variants (16-19), as well as metabolic 86 
adaptive transformations (20).  87 
Recent advances in whole-genome sequencing (WGS) techniques have provided insights into the 88 
evolutionary trajectories of adaptation of P. aeruginosa to the CF environment, particularly with 89 
regard to patho-adaptive mutations, such as those associated with antibiotic resistance (11, 21-90 
26). In this sense, “the mutational resistome” was recently defined as the set of mutations involved 91 
in modulation of antibiotic resistance levels in absence of horizontal gene transfer (27, 28). 92 
In a previous investigation, we studied the evolutionary trajectories of P. aeruginosa hypermutator 93 
lineages in long-term CF chronic infection (24). Comparative WGS analyses showed extensive 94 
within-patient genomic diversification, with populations composed of different sub-lineages that 95 
had coexisted for many years since the initial colonization of the patient. Importantly, certain 96 
genes were particularly enriched for mutations and underwent convergent evolution across the 97 
sub-lineages, suggesting that they are involved in the optimization process of the P. aeruginosa 98 
pathogenic fitness. Here, we characterize the mutational resistome and the antibiotic susceptibility 99 
profile of a hypermutator lineage sampled throughout a period of 20 years of evolution from the 100 
airways of a CF patient. To gain a comprehensive picture of the evolution of antibiotic resistance, 101 
we performed a longitudinal analysis by exploring WGS data of three sequentially isolated clones 102 
and a transversal study on a collection of 11 isolates obtained from a single sputum sample, which 103 
provided a snapshot of the genetic diversity at population level.  104 
  105 
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 RESULTS  106 
Emergence of multidrug-resistant isolates in the CFD collection. In our previous study, we 107 
sequenced whole genomes of 14 isolates belonging to the same clonal lineage of P. aeruginosa, 108 
spanning 20 years of a patient’s infection history (referred to as patient CFD) (24). This collection 109 
included a normo-mutator isolate obtained in 1991, which we used as the ancestral reference, two 110 
hypermutator isolates one from 1995 and the other from 2002, and 11 isolates obtained from the 111 
same sputum sample in 2011. 112 
All the hypermutator isolates harbor the same mutS mutation, which inactivates the MMR system 113 
(24). As shown in Fig. 1, patient CFD received prolonged treatment with a large and varied set of 114 
antibiotics during the course of chronic infection between 1986 and 2012. Treatment included five 115 
classes of antibiotics: β-lactams, aminoglycosides, quinolones, polymyxins and macrolides. To 116 
investigate the impact of antibiotic treatment on the resistance profiles of the CFD isolates, 117 
susceptibility to antibiotics representing all these major classes was tested by the agar diffusion 118 
method according to the CLSI guidelines. As observed in Fig. 2, all except for the 1991 isolate 119 
showed multidrug-resistance, meaning a reduced susceptibility to two or more classes of 120 
antibiotics. Starting from the general susceptible phenotype of the 1991 isolate, the 1995 exhibited 121 
resistance to β-lactams, whereas the 2002 isolate, in addition to β-lactams, gained resistance to 122 
ciprofloxacin, tobramycin, and colistin. Importantly, the collection of 2011 isolates showed the 123 
highest levels of resistance to ciprofloxacin, tobramycin, azithromycin, colistin and particularly 124 
to β-lactams such as cephalosporins and the monobactam aztreonam. Interestingly, in contrast to 125 
the 1995 isolate, the 2002 and all the 2011 isolates showed susceptibility to piperacillin-126 
tazobactam, resistance to which seems to have been lost after the acquisition of resistance to 127 
tobramycin, thus suggesting collateral sensitivity to penicillin-type-β-lactams as previously 128 
described by Barbosa et al. (29). On the other hand, even though colistin was used from 2004, all 129 
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isolates showed MIC values ranging from 8 to 32 µg/ml, which are relatively high compared to 130 
other data sets from clinical isolates (27, 28, 30, 31) (Fig. 2). Finally, although P. aeruginosa has 131 
no clinical breakpoints established for azithromycin, the evolved isolates showed relatively higher 132 
MICs than the 1991 and 1995 isolates. 133 
Mutations for antibiotic resistance are positively selected during evolution. In order to 134 
investigate the molecular bases of the antimicrobial resistance observed in CFD isolates, we 135 
explored the acquisition of mutations in a set of 168 chromosomal genes, here defined as the 136 
resistome, which have been described to be involved in P. aeruginosa antibiotic resistance 137 
mechanisms (27, 28, 32). Thus, using the 1991 genome as reference, we analyzed the distribution 138 
of a total of 5710 SNPs and 1078 indels accumulated in a period of 20 years of infection, which 139 
we have previously detected in the collection of isolates by WGS analysis (24). Furthermore, we 140 
also analyzed 39 SNPs (26 synonymous, 13 non-synonymous) detected in the genome sequence 141 
of the 1991 isolate when compared to the PAO1 genome. Sequence variations found within the 142 
resistome are documented in Supplementary Table 1 (Table S1). Interestingly, 93 (55%) of the 143 
168 investigated genes, showed non-synonymous SNPs and/or indels mutations of 1-3 bp in at 144 
least one of the isolates. On the other hand, 11 (6%) genes showed only synonymous mutations, 145 
and 64 (38%) showed no mutations (Fig. S1). Furthermore, 86 out of the 87 genes harboring non-146 
synonymous mutations (99%), were targeted with missense mutations, whereas a single gene (1%) 147 
showed a nonsense mutation (Fig. S1 and Table S1). By analyzing the ratio between non-148 
synonymous and synonymous mutations (dN/dS ratio) within the resistome in each CFD isolate 149 
(Table S2), we observed that in most isolates the signature of selection was higher than 1 and 150 
higher than the ratio obtained from SNPs affecting all the other genes (dN/dS=0.78). This indicates 151 
that these mutations were positively selected during chronic infection, and suggests that 152 
hypermutability may be linked to them as a key factor contributing to antibiotic resistance in CF. 153 
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Mutational resistome analysis was further focused on those genes that were targeted with non-154 
synonymous and/or frameshift mutations (Fig. 3), showing that accumulation of these mutations 155 
correlated with increased antibiotic resistance. Moreover, no mutations were detected in the 156 
ancestral 1991 isolate respect to the reference strain PAO1, in agreement with its general antibiotic 157 
susceptibility (Fig. 2). In some genes known to be involved in antibiotic resistance, single 158 
mutations were identified, such as D87G in GyrA and S278P in OprD (33, 34); in others, the 159 
accumulation of 3 to 5 different mutational events suggests that they have evolved under strong 160 
selective pressure. Such examples are amgS, mexX, fusA2 (involved in aminoglycoside resistance), 161 
mexF, oprN, poxB, mexI (involved in β-lactams resistance), polB, mexD, parE (involved in 162 
quinolone resistance), spuF (polyamines) and mexK (coding for a novel efflux system MexJK) 163 
(35). Remarkably, mexY, fusA1 (aminoglycoside resistance), ampC and ftsI (β-lactams resistance) 164 
accumulated more than 6 different mutations (Fig. 3), providing strong evidence for parallel 165 
evolution.  166 
The β-lactam resistome. As shown in Fig. 1, patient CFD received prolonged antibiotic courses 167 
with Ceftazidime as well as shorter courses of varying durations with different types of β-lactams, 168 
including other cephalosporins (Cefotaxime), penicillins (Piperacillin + tazobactam), 169 
monobactams (Aztreonam) and carbapenems (Thienamycin and Meropenem). As expected, 170 
resistance increased from the 1995 isolate to later isolates, reaching the highest resistance levels 171 
to cephalosporins, aztreonam and carbapenems in the 2011 isolates (Fig. 2). A total of 70 genes 172 
have been reported to be involved in the β-lactam resistome (27, 28), including: regulation of 173 
peptidoglycan-recycling genes (responsible for AmpC overproduction), genes encoding penicillin-174 
binding proteins (PBPs, targets of β-lactam antibiotics), or encoding regulators of efflux pumps 175 
such as mexAB-oprM (involved in β-lactam resistance) and mexEF-OprN (involved in 176 
carbapenem resistance) and, the oprD gene (involved in resistance to imipenem and susceptibility 177 
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to meropenem). We found that 42 of these 70 genes (60%) showed non-synonymous and/or 178 
frameshift mutations in at least one isolate of the CFD collection (Fig. 3). Of these 42 genes, 36 179 
showed accumulations of 1 to 2 mutations, most of them being unique to each specific cluster. It 180 
has been described that the emergence of resistance to penicillins and cephalosporins is mainly 181 
due to overproduction of the β-lactamase AmpC (36). However, the most frequent drivers of 182 
AmpC overproduction described in P. aeruginosa clinical strains, namely ampD, ampR and dacB 183 
(37-39), were not mutated among CFD isolates. Instead, all but the 1991 isolate showed a 184 
frameshift mutation in mpl, which encodes a UDP-N-acetylmuramate:l-alanyl-γ-d-glutamyl-meso-185 
diaminopimelate ligase, indicating that ampC could be overexpressed via this alternative negative 186 
regulator (40). Western blot analyses showed that all 2011 isolates showed an increased expression 187 
of AmpC compared to the 1991, 1995 and 2002 isolates, suggesting that alternative pathways may 188 
be responsible for AmpC overproduction in these isolates (Fig. S2). In addition, ampC was among 189 
the most mutated genes in the CFD collection together with the ftsI gene, showing 8 and 13 distinct 190 
missense mutations, respectively (Fig. 3). In fact, all CFD isolates, except 1991 and 1995, showed 191 
accumulation of mutations within ampC, with isolates from 2011 carrying up to four different 192 
mutations, combined in different ampC alleles. This strongly correlates with the increase in the 193 
MICs of cephalosporins and with aztreonam resistance in the evolved CFD isolates (Fig. 2), 194 
indicating that they were under high selective pressure during the CFD chronic infection process. 195 
Interestingly, the presence of mutations such as P154L, G216S and V213A, has been reported to 196 
be involved in β-lactam resistance (41). Likewise, all isolates except for 1991 showed mutations 197 
in ftsI, compared with isolates from 2011 showing up to six mutations combined in a single allele. 198 
Some of these mutations (Y367C, H394R, N427S, Q458R, Q475R, R504L, V523A, V523M and 199 
F533L) are located in the transpeptidase β-lactam binding site of the protein, and the latter mutation 200 
has been shown to play a key role in β-lactam recognition (42). Importantly, these mutations have 201 
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been documented to emerge among P. aeruginosa CF collections (28, 43, 44) and upon aztreonam 202 
exposure in vitro (45), whereas other mutations are described for the first time in this work (Table 203 
S1). The rest of the PBP encoding genes showed few mutations among the CFD collection.  204 
Although patient CFD received only short courses with carbapenems, we observed the emergence 205 
of high levels of resistance to carbapenems in all isolates except for the ancestral 1991 isolate. 206 
Previous reports have shown that loss of function mutations in the outer membrane protein OprD 207 
and/or overexpression of efflux pumps MexAB-OprM (meropenem resistance) and MexEF-OprN 208 
(imipenem and meropenem resistance) constitute main mechanisms to develop carbapenem 209 
resistance. However, only the 2002 isolate (Cluster I, defined according the phylogenetic tree 210 
showed in Figure 2) showed a missense mutation (S278P) within the oprD gene, which has been 211 
previously described to be involved in carbapenem resistance (34). Expression of the MexAB-212 
oprM system is controlled by the regulatory genes mexR, nalC and nalD (46, 47), and a missense 213 
mutation in nalC (M151T) was identified in the two isolates from Cluster V. Mutations F533L and 214 
R504 in PBP3 have been found to occur upon meropenem exposure during in vitro evolution 215 
studies and among CF patients treated with this drug (44, 48). Thus, high levels of carbapenem 216 
resistance may be associated with the presence of these ftsI mutations. Importantly, using 217 
ResFinder tool on WGS data from CFD isolates, we did not find genes coding for any class of β 218 
Metallo-beta-lactamases (MBLs) involved in carbapenem resistance, which are normally acquired 219 
through horizontal gene transfer (49). These results suggest that various different mutational 220 
mechanisms may be involved in carbapenem resistance in different coexisting CFD isolates, giving 221 
rise to distinct genetic pathways for the evolution of resistance to β-lactams. 222 
The aminoglycoside resistome. As shown in Fig. 1, patient CFD received extensive treatment 223 
courses of tobramycin. MIC determinations showed that all isolates, except for 1991 and 1995, 224 
became resistant to tobramycin. The main origin of high-level resistance to aminoglycosides is the 225 
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overexpression of MexXY-OprM efflux system (50), which is primarily caused by mexZ mutations 226 
(10, 21, 51). In addition, mutations in the amgRS and parRS two-component systems genes have 227 
also been involved in the regulation of MexXY expression (52). No mexZ mutations, however, 228 
were observed in the CFD collection of isolates, with the sole exception of isolate 2011_33 (Cluster 229 
VI), which showed a V29A mutation located within the DNA binding domain of the protein (Table 230 
S1) (53) and predicted to be deleterious (-3.351 PROVEAN v1.1.3). Instead, we found four 231 
different mutations in gene amgS, encoding the histidine kinase sensor of the membrane stress-232 
response two-component system, six mutations in mexY, encoding a component of the MexXY 233 
efflux pump, and six mutations in fusA1, which codes for the elongation factor G.  234 
MexY mutations have been frequently observed among drug-resistance isolates and CF epidemic 235 
clones (28, 31). Some mutations affect the general pump operation and impair the MexY-236 
dependent aminoglycoside resistance, whereas other mutations, located in domains associated with 237 
aminoglycoside recognition and export, may improve drug accommodation and consequently 238 
increase resistance (54). Furthermore, it was observed that the MexY mutation F1018L is able to 239 
increase pump-promoted resistance to aminoglycosides, cefepime, and fluoroquinolones (55). 240 
Importantly, here we describe for the first time the six mexY missense mutations. In this sense, 241 
their impact in MexXY pump function and aminoglycoside resistance remains unclear and 242 
deserves further investigation. 243 
Mutations in the amgS gene have been shown to be involved in intrinsic aminoglycoside resistance 244 
in P. aeruginosa (56). Although none of the four mutations in amgS found here have been 245 
previously reported (Table S1), all isolates from 2011 except 2011_33 showed an A203V mutation 246 
located within the linker HAMP domain. Interestingly, it has been reported that mutations in the 247 
linker domain of EnvZ, the closest E. coli homolog of AmgS, often cause activation of the kinase 248 
sensor (57, 58). Moreover, we found the P116L mutation, predicted to be deleterious (-2.539 249 
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PROVEAN v1.1.3). This mutation is located in the sensor domain of AmgS, where mutations 250 
involved in aminoglycoside resistance have been previously described (56). 251 
FusA1 mutations have been recently linked to the emergence of aminoglycoside resistance in vitro 252 
(59-61) as well as in clinical CF strains (28, 62-64). In fact, aminoglycoside resistance seems to 253 
be an indirect consequence of the alteration of elongation factor G (60). Isolate 2011_34 harbored 254 
two substitutions, V93A and D588G, located in domains G and IV of the protein, respectively, 255 
which have been reported to be gain-of-function mutations (28). Indeed, the V93A mutation was 256 
found to increase resistance to several aminoglycosides such as tobramycin, amikacin, and 257 
gentamycin (60). In several CFD isolates we identified four novel mutations in the fusA1 gene 258 
across the different domains of the protein sequence: domain II (V338A), domain III (A481V), 259 
domain IV (A595V) and domain V (Y683C). Isolate 1995, harboring the Y683C mutation, showed 260 
susceptibility to tobramycin (Fig. 2), suggesting that this mutation is not involved in 261 
aminoglycoside resistance. Moreover, Bolard et al. (60) recently reported that higher MICs are 262 
associated with mutations in domains II, IV and V, but not in domains G and III. Therefore, only 263 
mutations V338A (isolate 2002) and A595V (isolates 2011 from cluster III; Fig. 2) are expected 264 
to contribute to aminoglycoside resistance, although the effect of both substitutions needs to be 265 
characterized in future works. In conclusion, high-level of aminoglycoside resistance in the CFD 266 
population seems to have been acquired mostly by different mutations in the amgS and/or fusA1 267 
genes. 268 
The fluoroquinolone resistome. Patient CFD received two prolonged periods of treatment with 269 
ciprofloxacin, from 1992 to 2002 and from 2004 to 2012 (Fig. 1). MICs of ciprofloxacin revealed 270 
that most of the isolates exhibited high resistance levels to this antibiotic, whereas the 1991 and 271 
1995 isolates showed susceptibility and intermediate resistance, respectively (Fig. 2). High 272 
resistance to ciprofloxacin usually involves one or several mutations in quinolone resistance 273 
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determining (QRD) regions of the GyrAB subunits of topoisomerase II (gyrase), and the ParCE 274 
subunits of topoisomerase IV (28). Indeed, all CFD isolates except for the 1991, harbored the same 275 
D87G mutation in GyrA. In addition, isolate 2011_33 also carried a T83I mutation in this gyrase 276 
subunit. Importantly, both mutations are known to be involved in quinolone resistance (28, 31, 277 
33). Furthermore, two 2011 isolates from Cluster IV harbored an S618L substitution in GyrB. On 278 
the other hand, all isolates except for the 1991, accumulated mutations in the topoisomerase IV 279 
subunits ParC (P308L, T705A) and ParE (V199M, D462G, S492F), none of which have been 280 
previously described. Whether these mutations clustered in the chromosomally encoded 281 
topoisomerases II and IV were involved in quinolone resistance or were randomly fixed by genetic 282 
drift upon the high mutation supplies provided by hypermutability, remains to be elucidated. 283 
Nevertheless, the fact that many different mutations arose after fluoroquinolone treatments 284 
supports the previous observation that mutations involved in fluoroquinolone resistance can be 285 
highly variable (28). Importantly, with the use of the ResFinder tool we found the acquisition of a 286 
novel plasmid-encoded ciprofloxacin-modifying gene encoding the enzyme CrpP (65), which may 287 
explain the high-resistance profile observed in the two intermediate isolates from 1995 and 2002, 288 
and all isolates from 2011. 289 
Finally, we noticed that no mutations were observed in the negative regulator nfxB among the CFD 290 
isolates, which is commonly reported to achieve resistance to ciprofloxacin in a CF context due to 291 
the deregulation and concomitant overexpression of the efflux pump MexCD-OprJ (66). 292 
Furthermore, although all Cluster IV isolates from 2011 harbored a nonsense mutation in the 293 
transporter MexD (W1023STOP), which inactivates the efflux pump, it has been described that 294 
this mutation has no effect on the MIC of ciprofloxacin (67). 295 
The polymyxin resistome. Patient CFD received intensive treatment with colistin from 2004 to 296 
2011 (Fig. 1). According to CLSI, antibiotic susceptibility profiling revealed that every CFD 297 
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isolate was resistant to colistin (Fig. 2). However, the evolved 2011 isolates from cluster III, IV 298 
and V as well as the 2002 isolate, showed 2- to 4-fold increases in their MICs relative to 1991 and 299 
1995 isolates (8 μg/mL) (Fig. 2). Clinical strains of P. aeruginosa sometimes show resistance to 300 
polymyxins due to mutations in different two-component systems, such as PhoPQ, PmrAB, ParRS, 301 
CprRS and ColRS (68-72). Additionally, mutations causing derepression of the lipopolysaccharide 302 
(LPS) modifying (arn) operon, encoding the proteins necessary for the aminoarabinosylation of 303 
the lipid A moiety of the LPS, have been identified in colistin-resistant P. aeruginosa strains (30, 304 
70, 73). As shown in Fig. 3, the different CFD isolates accumulated unique mutations in genes 305 
phoP, pmrB, parR, colR and colS genes, which may affect each of the mentioned two-component 306 
systems. In fact, the 2002 isolate harbored a A45T mutation in ParR located in the receiver domain 307 
and close to the conserved phosphorylation residue D57, which was previously shown to be 308 
involved in colistin resistance (74). On the other hand, considering that mutations V30A in PhoP, 309 
and D138N in ColR were present in the more susceptible 1995 isolate, the increased resistance 310 
observed in the 2011 evolved isolates from clusters III, IV and V could be explained by the 311 
presence of mutations in PmrB (T132A), CprS (G396S), and/or ColS (T138A). These novel 312 
mutations are the first to suggest their contribution to polymyxin resistance and therefore need to 313 
be further explored. 314 
Other antibiotics. From the beginning of 2004 to 2012, patient CFD received systematic long-315 
term treatments with azithromycin combined with other antipseudomonal agents. Although 316 
macrolide resistance is frequent among CF isolates, only two reports describe the emergence of 317 
macrolide resistance in vivo (32, 75). As shown in Fig. 2, MICs of azithromycin for the later 318 
isolates within the 2011 collection showed a 4-fold increase or more, relative to the ancestral 319 
isolate from 1991. Consistent with this, all 2011 isolates carried mutations in gene PA4280.2, 320 
which encodes the 23S ribosomal subunit. In fact, isolate 2011_33 carried an A2044G substitution, 321 
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whereas the remaining isolates from 2011 carried a C2597T mutation, both located in the 322 
secondary structure of domain V of the ribosomal RNA gene and previously reported to confer 323 
macrolide resistance (32, 75). Thus, macrolide resistance in coexisting CFD 2011 isolates was 324 
acquired by distinct mutations in the same gene. This provides additional evidence for parallel 325 
molecular evolution at population level, with antibiotic chemotherapy as the key selection force 326 




The high prevalence of hypermutator clones in CF chronic infections is a matter of great relevance 329 
because their link to antibiotic resistance hampers infection management (8-10, 14, 24, 76). In this 330 
study, we explored the evolution of the mutational antibiotic resistome of a P. aeruginosa 331 
hypermutator lineage by combining a longitudinal and a transversal analysis that covered 20 years 332 
of CF chronic infection. Antibiotic resistance increased as infection progressed towards the 333 
establishment of a population consisting of genotypically diversified coexisting sub-lineages, all 334 
of which converged to multi-drug resistance. Particularly, while mutations observed in amgS are 335 
most likely altering the MexXY pump regulation, mutations affecting other multi-drug efflux 336 
pump regulators were only rarely observed among CFD isolates. Instead, multidrug resistance 337 
emerged through the combination of multiple resistance mutations in several independent loci.   338 
Hypermutators can be indirectly selected for and fixed by their genomic association with fitness-339 
improving alleles (77-80). Particularly, under selective conditions imposed by long-term antibiotic 340 
therapy in the CF airways, de novo beneficial mutations can be expected to accumulate over time. 341 
Early mutational events occurring during the course of long-term infection are expected to have a 342 
strong impact on the resistance phenotype and consequently on fitness. Later mutations, many of 343 
them compensatory, may lead to fine tuning of the activity/stability of the resistance related 344 
proteins, in which epistatic interactions may play important roles for the trajectories of resistance 345 
development (81-84). P. aeruginosa carries many different genes, which upon functional 346 
mutations provide a resistance phenotype (27, 28). Identification of these genes and the associated 347 
polymorphisms involved in resistance document how many of them converge through distinct 348 
genetic pathways to the same or similar resistance profiles (26, 85, 86).  349 
Hypermutability increases the likelihood of reaching the most appropriate combinations in 350 
adaptive terms. Considering the multiple genetic pathways in P. aeruginosa behind different 351 
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resistance mechanisms, our observations show how hypermutability increases the probability of 352 
exploiting these distinct pathways, which eventually converge towards antibiotic multi-resistance 353 
in the course of long-term chronic infections.  354 
We show how aggressive and persistent chemotherapy targeting a hypermutator population 355 
resulted in repeated but independent mutagenic events in resistance associated genes, providing 356 
clear evidence of parallel evolution in clones of the CFD population. This was for example the 357 
case with ampC and fstI, which for the CFD lineage constituted hot spots for the accumulation of 358 
mutations involved in β-lactam antibiotic resistance (39, 41, 48, 49). Some of these mutations have 359 
been previously described, whereas others are reported here for the first time. Most interestingly, 360 
novel alleles were observed, each harboring a combination of 2 to 6 mutations.  361 
Overproduction of the β-lactamase AmpC is considered to be the main cause of resistance to first- 362 
and second- generation cephalosporins as well as aminopenicillins in P. aeruginosa clinical strains 363 
(36). However, P. aeruginosa is also able to adapt to new and more effective β-lactams (87), 364 
through a variety of mutations affecting the AmpC β-lactamase (41, 48, 88). Here, we document 365 
the confluence of both strategies: variants overproducing AmpC, in which the combination of 366 
distinct mutations may contribute to even higher levels of resistance and/or substrate spectrum 367 
extension. Furthermore, the accumulation of several different mutations in the penicillin-binding 368 
protein PBP3 may be a complementary and/or additional pathway. PBP3 relevance in β-lactam 369 
resistance, including the new generation cephalosporins and carbapenems, has been very recently 370 
confirmed (27, 28, 31, 43, 48). The high number of different mutations clustered in both ampC 371 
and fstI genes combines into innovative resistance-conferring alleles, which demonstrate how 372 
drug-resistance mutations can become highly beneficial when combined with compensatory 373 
mutations, and thus document the extraordinary ability of P. aeruginosa to develop antibiotic 374 
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resistance. In this context, the emergence of such innovative alleles may be distinctly favored by 375 
hypermutator phenotypes, then limiting our available therapeutic arsenal.  376 
How can we understand co-existence of many different genetic variants showing the same 377 
resistance profile in patient airways, such as it has been documented here? One answer is based on 378 
the balance between clonal interference and multiple mutations (89, 90). We thus argue that 379 
hypermutability increases the rate of antibiotic resistance evolution by increasing piggy-backing 380 
of multiple resistance mutations, causing maintenance of a diversified population where adaptive 381 
variation is sustained by a dynamic equilibrium between mutation and selection. Moreover, in 382 
long-term evolutionary scenarios such as chronic infections, the selective forces imposed by 383 
antibiotics along with high mutation rates from hypermutability, may shape genetically diverse 384 
populations able to respond successfully to antibiotic treatments ensuring persistence of the 385 
bacterium. 386 
Our results provide new evidence concerning the way in which hypermutators can expedite the 387 
evolution of multidrug-resistance by increasing the probability of acquiring adaptive mutations to 388 
support long-term survival of P. aeruginosa in the airways of CF patients.  389 
  390 
19 
 
MATERIALS AND METHODS 391 
P. aeruginosa CFD collection. Clinical P. aeruginosa isolates were obtained from sputum 392 
samples from a CF patient attending the Copenhagen CF Centre at Rigshospitalet (Copenhagen, 393 
Denmark) (patient CFD). In a previous study (24), we sequenced the genomes of 14 isolates from 394 
this patient covering  ̴ 20 years of the patient lifespan (European Nucleotide Archive, ENA/SRA 395 
ERP002379). The CFD collection included: One normo-mutator isolate obtained in 1991 396 
(CFD_1991) five years after the onset of chronic P. aeruginosa infection in 1986; two sequential 397 
mismatch repair (MRS) deficient mutators from 1995 (CFD_1995) and 2002 (CFD_2002) that 398 
harbored the same ΔCG mutation in mutS at position 1551; and 11 P. aeruginosa isolates obtained 399 
from a single sputum sample in 2011 (CFD_2011), all harboring the ΔCG mutS mutation at 1551 400 
and belonging to the same hypermutator lineage. 401 
Profiling of antibiotic resistance genes. In order to correlate the documented resistance 402 
genotypes with the observed resistance phenotypes, single-nucleotide polymorphisms (SNPs) and 403 
indels (1- to 10-bp insertion/deletion mutations) for each isolate obtained from the previous study 404 
(24) were filtered based on an exhaustive literature review (27, 28). We also added PA0668.4, 405 
PA4280.2, PA4690.2 and PA5369.2 genes to the list, affecting macrolide resistance (32). Thus, 406 
we obtained a set of 168 genes known to be related to antibiotic resistance in P. aeruginosa. Indels 407 
and premature stop codons were considered to result in the inactivation of the corresponding 408 
protein product. The contribution of the documented SNPs to the phenotype was evaluated 409 
according to the available literature and by using online software tools for prediction of the effect 410 
of nucleotide substitutions on protein function, e.g. SIFT (91), PROVEAN (92) and SNAP2 (93). 411 
In addition, the online tool ResFinder v2.1 (https://cge.cbs.dtu.dk//services/ResFinder/) (94) was 412 
used to identify possible horizontally acquired antimicrobial resistance genes. 413 
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Susceptibility testing. MICs determination was performed by using the broth dilution method, 414 
according to Clinical and Laboratory Standards Institute (CLSI) guidelines and breakpoints (95). 415 
Ten antimicrobials agents from five classes of antibiotics were tested. From the β-lactam class, 416 
shown as ≤susceptible/≥resistant breakpoints, ceftazidime (8/32µg/ml), cefepime (8/32µg/ml), 417 
piperacillin/tazobactam (16-4/128-4µg/ml), aztreonam (8/32µg/ml), imipenem (2/8 µg/ml) and 418 
meropenem (2/8 µg/ml) were used. Aminoglycosides: tobramycin (4/16µg/ml); fluoroquinolones: 419 
ciprofloxacin (0.5/2µg/ml); polymyxins: colistin (2/4µg/ml); macrolides: azithromycin (no 420 
information). P. aeruginosa ATCC 27853 was used as quality control strain.  421 
AmpC expression levels. CFD isolates were grown for 16 h on LB media and 1.5 mL of each 422 
culture was pelleted and resuspended in 20 mM Tris-HCl (pH 7.4), 0.5 M NaCl, 15% glycerol, 423 
amended with 0.2 mg/ml lysozyme, 1 mM 8 phenylmethylsulfonyl fluoride and 1 mM 424 
benzamidine, and incubating for 1 h on ice. After four sonication (2 min) and freeze/unfreeze 425 
cycles, intact cells were removed by centrifugation at 9000 g for 20 min and the extracts were 426 
stored at -20˚C. 25μg of total proteins were separated through sodium dodecyl sulfate (SDS)- 427 
polyacrylamide gel electrophoresis (PAGE) 12%, then proteins were transferred to 428 
polyvinylidene fluoride (PVDF) membranes for 1.5 hours at 350 mA. The blots were blocked for 429 
one hour in 5% milk in phosphate-buffered saline (PBS) solution at room temperature. 430 
Incubation with primary antibody (rabbit anti-PDC-3 policlonal, (96), was added at 1/1,000 431 
overnight at 4˚C in 5% milk/PBS, then washings were performed with PBS/Tween 20, and the 432 
secondary antibody (IRDye 680RD anti-rabbit, LI-COR) was added at a 1:20,000 dilution for 1 433 
hour in 5% milk/PBS. Membranes were scanned on Odyssey infrared imager instrument (LI-434 
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Figure 1. Overview of isolate sampling time points and antibiotic treatment. 756 
 757 
P. aeruginosa isolates were collected from patient CFD between 1991 and 2011. +/- symbols 758 
indicate hypermutability state of P. aeruginosa strains. Antibiotics used in chemotherapy through 759 
the 20 years study are listed in the Y axis. Grey circles indicate the start and end of an antibiotic 760 







Figure 2. Antibiotic resistance profiles of P. aeruginosa isolates from the CFD lineage. Each 766 
column represents the Minimal Inhibitory Concentration (MIC) values of the different antibiotic 767 
tested: piperacillin-tazobactam (TZP); ceftazidime (CAZ); cefepime (FEP);; aztreonam (ATM); 768 
imipenem (IMI); meropenem (MEM); ciprofloxacin (CIP); tobramycin (TOB); colistin (CST) and 769 
azithromycin (AZM). Red intensity indicates MIC levels for each antibiotic. Asterisks (*) indicate 770 
resistance according to CLSI. Left tree represents the genetic clustering of isolates (rows) based 771 
on the result of maximum-parsimony analysis. The phylogenetic tree on the left was constructed 772 




Figure 3. Resistome of the CFD isolate collection.  775 
Mutations potentially affecting protein function in 93 out of the 168 antibiotic resistance genes 776 
were analyzed. Genes and variants were grouped by antibiotic class. Upper panel: number of 777 
independent mutations found within each specific gene along the CFD lineage. Lower panel: 778 
heatmap of the number of mutations accumulated per gene in each genome. Isolates were grouped 779 
based on the genetic clustering defined in Fig. 2. *Asterisks indicate genes which are also involved 780 









SUPPLEMENTARY LEGENDS 788 
Figure S1. Analysis of type of mutations found in antibiotic resistance genes in P. aeruginosa 789 
isolates from CFD patient. 790 
Pie charts indicate the observed percentage for each kind of mutation respect to the total number 791 
of mutations occurring in the 168 belonging to the P. aeruginosa resistome.  792 
Figure S2. Western blot of CFD isolates.   793 
Total proteins (25μg) were obtained from whole-cell lysates from each P. aeruginosa clinical 794 
isolates, resolved in a 12% polyacrylamide gel, and tested with a PDC-3 antibody.  795 
Table S1. Nonsynonymous and frameshift mutations found within 93 out of 168 antibiotic 796 
resistance genes in CFD collection. 797 
Table S2. Number of genes mutated and type of mutations found in the sequenced 798 
genomes.  799 
